{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:09:40Z","timestamp":1784761780622,"version":"3.55.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review provides an assessment of biomarkers in sarcoidosis, aiming to address the need for improved diagnostic, prognostic and management tools. Sarcoidosis presents diagnostic challenges, necessitating the search for reliable biomarkers to guide clinical decisions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Established biomarkers such as serum angiotensin-converting enzyme (ACE) and serum interleukin-2 receptor (sIL-2R) have limitations in sensitivity and specificity. FDG-PET\/CT imaging shows promising results in assessing disease activity and guiding immunosuppression. Gene expression profiling studies reveal potential biomarkers, particularly involving TH1 immune response and IFN-\u03b3-driven signalling pathways. The field of omics sciences offers opportunities for novel biomarker discovery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>These findings have implications for clinical practice and research. The limitations of established biomarkers underscore the need for improved diagnostic tools in sarcoidosis. The potential of FDG-PET\/CT imaging requires further exploration. Gene expression profiling and omics sciences offer avenues for discovering novel biomarkers to enhance diagnosis and predict disease progression. Such advancements can facilitate personalized treatment strategies and improve patient outcomes. Continued research is vital to validate the efficacy and clinical applicability of these biomarkers. Overall, this review emphasizes ongoing efforts to advance sarcoidosis biomarkers research and improve disease management.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mcp.0000000000000985","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T12:05:31Z","timestamp":1688645131000},"page":"478-484","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Personalized medicine in sarcoidosis: unravelling biomarkers for targeted care"],"prefix":"10.1097","volume":"29","author":[{"given":"Joel","family":"Francesqui","sequence":"first","affiliation":[{"name":"Pulmonology Department, Hospital General de Granollers"},{"name":"WASOG Centre of Excellence, Respiratory Institute, Pulmonology Department, Hospital Cl\u00ednic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Marrades","sequence":"additional","affiliation":[{"name":"WASOG Centre of Excellence, Respiratory Institute, Pulmonology Department, Hospital Cl\u00ednic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobo","family":"Sellares","sequence":"additional","affiliation":[{"name":"WASOG Centre of Excellence, Respiratory Institute, Pulmonology Department, Hospital Cl\u00ednic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/1744666X.2019.1568240","article-title":"Clinically-useful serum biomarkers for diagnosis and prognosis of sarcoidosis","volume":"15","author":"Ramos-Casals","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"R2-20250730","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jama.2022.1570","article-title":"Diagnosis and treatment of pulmonary sarcoidosis: a review","volume":"327","author":"Belperio","year":"2022","journal-title":"JAMA"},{"key":"R3-20250730","doi-asserted-by":"crossref","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"R4-20250730","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1148\/rg.306105512","article-title":"Pulmonary sarcoidosis: typical and atypical manifestations at high-resolution CT with pathologic correlation","volume":"30","author":"Criado","year":"2010","journal-title":"Radiographics"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1378\/chest.127.1.185","article-title":"Long-term follow-up CT scan evaluation in patients with pulmonary sarcoidosis","volume":"127","author":"Akira","year":"2005","journal-title":"Chest"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-0037-1603765","article-title":"Imaging for sarcoidosis","volume":"38","author":"Calandriello","year":"2017","journal-title":"Semin Respir Crit Care Med"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.rmed.2012.11.011","article-title":"Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis","volume":"107","author":"Mostard","year":"2013","journal-title":"Respir Med"},{"key":"R8-20250730","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1378\/chest.07-1178","article-title":"Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis","volume":"132","author":"Teirstein","year":"2007","journal-title":"Chest"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1378\/chest.12-2479","article-title":"Accuracy of individual variables in the monitoring of long-term change in pulmonary sarcoidosis as judged by serial high-resolution CT scan data","volume":"145","author":"Zappala","year":"2014","journal-title":"Chest"},{"key":"R10-20250730","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cca.2019.10.010","article-title":"Combined application of angiotensin converting enzyme and chitotriosidase analysis improves the laboratory diagnosis of sarcoidosis","volume":"500","author":"Enyedi","year":"2020","journal-title":"Clin Chim Acta"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"458","DOI":"10.12659\/PJR.897708","article-title":"Serum ACE level in sarcoidosis patients with typical and atypical HRCT manifestation","volume":"81","author":"Kahkouee","year":"2016","journal-title":"Pol J Radiol"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.rmed.2014.11.009","article-title":"ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy","volume":"109","author":"Vorselaars","year":"2015","journal-title":"Respir Med"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/biom8030084","article-title":"YKL-40, soluble IL-2 receptor, angiotensin converting enzyme and C-reactive protein: comparison of markers of sarcoidosis activity","volume":"8","author":"Uysal","year":"2018","journal-title":"Biomolecules"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12931-019-1263-z","article-title":"Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis","volume":"21","author":"Bennett","year":"2020","journal-title":"Respir Res"},{"key":"R15-20250730","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s10875-012-9754-4","article-title":"Human chitotriosidase: a sensitive biomarker of sarcoidosis","volume":"33","author":"Bargagli","year":"2013","journal-title":"J Clin Immunol"},{"key":"R16-20250730","doi-asserted-by":"crossref","first-page":"8565423","DOI":"10.1155\/2019\/8565423","article-title":"Prognostic biomarkers of sarcoidosis: a comparative study of serum chitotriosidase, ACE, lysozyme, and KL-6","volume":"2019","author":"Bergantini","year":"2019","journal-title":"Dis Markers"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1159\/000446606","article-title":"Diagnostic value of the CD103+CD4+\/CD4+ ratio to differentiate sarcoidosis from other causes of lymphocytic alveolitis","volume":"91","author":"Bretagne","year":"2016","journal-title":"Respiration"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1080\/1744666X.2016.1196135","article-title":"Biomarkers in sarcoidosis","volume":"12","author":"Chopra","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1183\/09031936.00055213","article-title":"Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis","volume":"43","author":"Vorselaars","year":"2014","journal-title":"Eur Respir J"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/MCP.0000000000000303","article-title":"T-cell immunology in sarcoidosis: disruption of a delicate balance between helper and regulatory T-cells","volume":"22","author":"Broos","year":"2016","journal-title":"Curr Opin Pulm Med"},{"key":"R21-20250730","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1164\/rccm.201507-1499OC","article-title":"IFN-\u03b3-producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-Helper Type 1 cells","volume":"193","author":"Ramstein","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaut.2018.07.012","article-title":"Molecular profiling of regulatory T cells in pulmonary sarcoidosis","volume":"94","author":"Kachamakova-Trojanowska","year":"2018","journal-title":"J Autoimmun"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10238-019-00578-3","article-title":"NK and NKT-like cells in granulomatous and fibrotic lung diseases","volume":"19","author":"Bergantini","year":"2019","journal-title":"Clin Exp Med"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000521467","article-title":"The role of serum galectin-3 levels in patients with sarcoidosis","volume":"31","author":"Kara","year":"2022","journal-title":"Med Princ Pract"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"1012827","DOI":"10.3389\/fmed.2022.1012827","article-title":"Biochemical and genomic identification of novel biomarkers in progressive sarcoidosis: HBEGF, eNAMPT, and ANG-2","volume":"9","author":"Casanova","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/MCP.0000000000000892","article-title":"The role of PET in the management of sarcoidosis","volume":"28","author":"Vender","year":"2022","journal-title":"Curr Opin Pulm Med"},{"key":"R27-20250730","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.amjcard.2015.08.025","article-title":"F-18-fluorodeoxyglucose positron emission tomography-guided sampling of mediastinal lymph nodes in the diagnosis of cardiac sarcoidosis","volume":"116","author":"Simonen","year":"2015","journal-title":"Am J Cardiol"},{"key":"R28-20250730","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/bjo.2010.194514","article-title":"Intraocular sarcoidosis: association of clinical characteristics of uveitis with findings from 18F-labelled fluorodeoxyglucose positron emission tomography","volume":"96","author":"Rahmi","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R29-20250730","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.rmed.2011.08.012","article-title":"Inflammatory activity assessment by F18\u200aFDG-PET\/CT in persistent symptomatic sarcoidosis","volume":"105","author":"Mostard","year":"2011","journal-title":"Respir Med"},{"key":"R30-20250730","first-page":"123","article-title":"18F-FDG PET as a predictor of pulmonary function in sarcoidosis","volume":"28","author":"Keijsers","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"R31-20250730","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur Respir J"},{"key":"R32-20250730","first-page":"1823710","article-title":"The utility of 18F-FDG PET\/CT for monitoring response and predicting prognosis after glucocorticoids therapy for sarcoidosis","volume":"2018","author":"Chen","year":"2018","journal-title":"Biomed Res Int"},{"key":"R33-20250730","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.hrthm.2014.03.043","article-title":"HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis","volume":"11","author":"Birnie","year":"2014","journal-title":"Heart Rhythm"},{"key":"R34-20250730","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cardfail.2019.02.018","article-title":"Serial cardiac FDG-PET for the diagnosis and therapeutic guidance of patients with cardiac sarcoidosis","volume":"25","author":"Ning","year":"2019","journal-title":"J Card Fail"},{"key":"R35-20250730","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.chest.2022.10.037","article-title":"Efzofitimod for the treatment of pulmonary sarcoidosis","volume":"163","author":"Culver","year":"2022","journal-title":"Chest"},{"key":"R36-20250730","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"R37-20250730","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"R38-20250730","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"R39-20250730","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R40-20250730","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1183\/09031936.00224513","article-title":"Rituximab in the treatment of refractory pulmonary sarcoidosis","volume":"43","author":"Sweiss","year":"2014","journal-title":"Eur Respir J"},{"key":"R41-20250730","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00408-017-9994-4","article-title":"Repository corticotropin for chronic pulmonary sarcoidosis","volume":"195","author":"Baughman","year":"2017","journal-title":"Lung"},{"key":"R42-20250730","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/s41467-022-30615-x","article-title":"Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis","volume":"13","author":"Damsky","year":"2022","journal-title":"Nat Commun"},{"key":"R43-20250730","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/thoraxjnl-2012-202772","article-title":"The COPD control panel: towards personalised medicine in COPD","volume":"68","author":"Agusti","year":"2013","journal-title":"Thorax"},{"key":"R44-20250730","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/MCP.0000000000000194","article-title":"Personalized medicine in sarcoidosis: predict responders and nonresponders","volume":"21","author":"Petrek","year":"2015","journal-title":"Curr Opin Pulm Med"},{"key":"R45-20250730","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MCP.0000000000000403","article-title":"Transcriptome profiles in sarcoidosis and their potential role in disease prediction","volume":"23","author":"Schupp","year":"2017","journal-title":"Curr Opin Pulm Med"},{"key":"R46-20250730","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.3390\/jcm10112222","article-title":"Novelties in imaging of thoracic sarcoidosis","volume":"10","author":"Calandriello","year":"2021","journal-title":"J Clin Med"},{"key":"R47-20250730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40484-016-0061-6","article-title":"RADIOTRANSCRIPTOMICS\u2019: a synergy of imaging and transcriptomics in clinical assessment","volume":"4","author":"Katrib","year":"2016","journal-title":"Quant Biol"},{"key":"R48-20250730","doi-asserted-by":"crossref","first-page":"100137","DOI":"10.1016\/j.opresp.2021.100137","article-title":"Sarcoidosis phenotypes","volume":"3","author":"Francesqui","year":"2021","journal-title":"Open Respir Arch"}],"container-title":["Current Opinion in Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCP.0000000000000985","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T22:04:54Z","timestamp":1753913094000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCP.0000000000000985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mcp.0000000000000985","relation":{},"ISSN":["1070-5287","1531-6971"],"issn-type":[{"value":"1070-5287","type":"print"},{"value":"1531-6971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]}}}